| P50 | author | Virginia Bosó | Q46800316 |
| | María José Herrero | Q46800335 |
| P2093 | author name string | Luis Rojas | |
| | Salvador F Aliño | |
| | José Luis Poveda | |
| | María Remedios Marqués | |
| | Ana Santaballa | |
| | Joaquin Montalar | |
| | Laura Palomar | |
| | Helena de la Cueva | |
| | Juan E Megias | |
| P2860 | cites work | Impact of genetic polymorphisms in CYP2C8 and rosiglitazone intake on the urinary excretion of dihydroxyeicosatrienoic acids | Q46730792 |
| | Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia | Q46738241 |
| | Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer | Q46958963 |
| | Pharmacogenomics knowledge for personalized medicine | Q24623166 |
| | Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics | Q27851471 |
| | Microtubules as a target for anticancer drugs | Q28253993 |
| | Repression of gene expression by oxidative stress | Q28679172 |
| | Taxane pathway | Q34390370 |
| | ERCC1 and ERCC2 haplotype modulates induced BPDE-DNA adducts in primary cultured lymphocytes | Q34672604 |
| | Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia | Q35148088 |
| | Advances in breast cancer: pathways to personalized medicine | Q35951346 |
| | Pharmacogenetic pathway analysis of docetaxel elimination. | Q36182023 |
| | CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel | Q36862832 |
| | Managing premedications and the risk for reactions to infusional monoclonal antibody therapy | Q37202488 |
| | A mitochondrial target sequence polymorphism in manganese superoxide dismutase predicts inferior survival in breast cancer patients treated with cyclophosphamide | Q37229749 |
| | Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney disease | Q37259666 |
| | Pharmacogenetics in breast cancer therapy | Q37352437 |
| | Pharmacogenetics of breast cancer therapies | Q37633176 |
| | Pharmacogenomics of taxane/platinum therapy in ovarian cancer | Q37643317 |
| | Paclitaxel induces apoptosis in breast cancer cells through different calcium--regulating mechanisms depending on external calcium conditions | Q37645271 |
| | Pharmacogenetics in breast cancer: focus on hormone therapy, taxanes, trastuzumab and bevacizumab | Q37725978 |
| | Pharmacogenomics of paclitaxel | Q37736449 |
| | Part 1: background, methodology, and clinical adoption of pharmacogenetics | Q37883726 |
| | Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy | Q37955505 |
| | Pharmacogenetics of taxanes: impact of gene polymorphisms of drug transporters on pharmacokinetics and toxicity. | Q38065218 |
| | Germline pharmacogenetics of paclitaxel for cancer treatment | Q38120289 |
| | PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8. | Q38130410 |
| | Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. | Q40773486 |
| | Association of CYP1B1 with hypersensitivity induced by taxane therapy in breast cancer patients | Q42969839 |
| | SNPs in genes coding for ROS metabolism and signalling in association with docetaxel clearance | Q43161301 |
| | Phenyl N-tert-butylnitrone, a free radical scavenger, reduces mechanical allodynia in chemotherapy-induced neuropathic pain in rats | Q43196088 |
| | Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity | Q43496569 |
| | Direct effect of Taxol on free radical formation and mitochondrial permeability transition | Q43702905 |
| | The Ala16Val genetic dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria | Q44346876 |
| | Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study | Q46128074 |
| | Pharmacogenetic studies of Paclitaxel in the treatment of ovarian cancer | Q46163330 |
| P433 | issue | 15 | |
| P304 | page(s) | 1845-1858 | |
| P577 | publication date | 2014-01-01 | |
| P1433 | published in | Pharmacogenomics | Q15724625 |
| P1476 | title | SNPs and taxane toxicity in breast cancer patients | |
| P478 | volume | 15 | |